Medical researchers in Armenia claim to have synthesized two new compounds that inhibit enzymes that contribute to the development of Alzheimer’s disease.

Armenia’s Academy of Sciences reports that the compounds were synthesized at its Organic and Pharmaceutical Chemistry Center.

“The basis of Alzheimer's disease is the pathological activity of amyloid beta peptides. Amyloid beta has a toxic effect on neurons in the brain and disrupts intercellular communication,” the statement reads, adding that the new compounds reduce the aggregation process of amyloid beta peptides and destroy the toxic aggregates formed by the peptides.

Alvard Antonyan, who heads the Institute of Biochemistry says further preclinical research will make it possible to create new drugs to prevent and treat the disease.

Research results, according to the statement, have been accepted for publication by the Journal of Neurochemistry.